• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ObsEva SA

News headline image
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
April 03, 2024
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Update on Board of Directors
March 19, 2024
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
February 28, 2024
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
Geneva Court Grants Temporary Moratorium to ObsEva
January 31, 2024
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
November 30, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
Organon Returns Ebopiprant to XOMA
October 27, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Files half Year 2023 Financial Statements
September 27, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Recovers Full Worldwide Rights on Nolasiban
July 13, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
Annual General Meeting 2023
June 08, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
May 02, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Change of Central Securities Depositary
April 20, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Files Year End 2022 Financial Statements
March 31, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
March 15, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
March 13, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
February 24, 2023
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Dismissal of Moratorium Proceedings
December 19, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 14, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
December 09, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
December 01, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 26, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 13, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
News headline image
ObsEva Announces Corporate Updates
July 27, 2022
From ObsEva SA
Via GlobeNewswire
Tickers OBSV
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap